Figure 2 | British Journal of Cancer

Figure 2

From: A quality-adjusted survival analysis (Q-TWiST) of rituximab plus CVP vs CVP alone in first-line treatment of advanced follicular non-Hodgkin's lymphoma

Figure 2

Gain function of incremental mean differences in Q-TWiST between R-CVP and CVP as a function of time (53 months’ median follow-up truncated at 67 months). The solid line represents the incremental mean differences in Q-TWiST over time with utilities 0.618 for TOX and REL and 1.0 for TWiST, whereas the shaded area depicts the range of differences in Q-TWiST, as the utility values for REL and TOX vary between 0 and 1.

Back to article page